![]() Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.Elevations in Creatinine Phosphokinase by CTCAE GradingĮTable 8. Summary of Serious Adverse Events by System Organ Class and Preferred TermĮTable 7. Summary of Patients Rescued and Rescue Medications UsedĮTable 6. Mean Gram Quantity of Sponsor-Provided Topical Corticosteroids Used Over 16 Weeks in the Intent-to-Treat Population, Responders Population, and Non-Responders PopulationĮTable 5. Mean Number of Days and Proportion of Time Without Use of Background Topical Corticosteroids Over 16 Weeks in the Intent-to-Treat Population, Responders Population, and Nonresponders PopulationĮTable 4. Other Efficacy and Health Outcomes Secondary Endpoints in the Intent-to-Treat PopulationĮTable 3. Summary of Atopic Dermatitis Treatment History at BaselineĮTable 2. Mean Proportion of Time Without Use of Background Topical Corticosteroids and Mean Gram Quantity of Sponsor-Provided Moderate Potency Topical Corticosteroids Used Over 16 Weeks in the Intent-To-Treat Population, Responders Population, and Nonresponders PopulationĮTable 1. Change From Baseline in the Total DLQI Score and the Proportion of Patients Achieving a DLQI Score of 0 or 1 Over TimeĮFigure 11. Change From Baseline in the Total POEM Score and the Proportion of Patients Achieving a ≥4-Point Improvement in the Total POEM Score Over TimeĮFigure 10. Proportion of Patients Achieving a ≥1.5-Point Improvement in the ADSS Item 2 Score Over TimeĮFigure 9. Change From Baseline in Skin Pain NRS Over TimeĮFigure 8. Proportion of Patients Achieving a ≥4-Point Improvement in the Itch NRS Response During the First Week of TreatmentĮFigure 7. Percent Change From Baseline in Itch NRS Over TimeĮFigure 6. Percent Change From Baseline in the Total EASI Score and Proportion of Patients Achieving a 90% Improvement in the Total EASI Score Over TimeĮFigure 5. ![]() ![]() Results for Graphical Multiple-Testing Procedure: EUĮFigure 4. Results for Graphical Multiple-Testing Procedure: US/JapanĮFigure 3. Study Investigators, Inclusion Criteria, and Exclusion CriteriaĮFigure 2.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |